Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Recruiting now
Conditions studied: Myeloproliferative Neoplasm
In brief
Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.
Key facts
- Study ID
- NCT05839717
- Run by
- University Hospital, Bordeaux
- People needed
- 120
- Starts
- 2023-06-19
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2024-12-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patient (age ≥ 18 years)
- Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional), before introduction of a cytoreductive treatment
- Patient carrying a JAK2V617F mutation
- Subject registered with a social security scheme
- Written informed consent obtained
- Acceptance of inclusion in the FIMBANK registry (specific consent form needed)
You may not qualify if…
- ET or PV Patient not carrying a JAK2V617F mutation
- Patient with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling
- Person under judicial safeguards, trustee or curatorship
- Person unable to give her consent
- Non-cooperative person
- Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion
Where it is running
- CHU d'Angers, Service Maladies du Sang — Angers, France (enrolling)
- CH de Bayonne, Service Hématologie Clinique — Bayonne, France (enrolling)
- CHU de Bordeaux, Service Médecine Interne et Maladies Infectieuses — Bordeaux, France (enrolling)
- Institut Bergonié, Service Hématologie Clinique — Bordeaux, France (enrolling)
- CHU de Brest, Service Hématologie Clinique — Brest, France (enrolling)
- CH de Dax, Service Hématologie Clinique — Dax, France (enrolling)
- CH de Libourne, Service Hématologie Clinique — Libourne, France (enrolling)
- CH de Mont de Marsan, Service Oncologie — Mont-de-Marsan, France (enrolling)
- CHU de Bordeaux, Service Hématologie Biologie — Pessac, France (enrolling)
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire — Pessac, France (enrolling)
- CHU de Bordeaux, Service Médecine Interne — Pessac, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.